News

The deal will also see the Canadian firm sell certain rights to plasma products and technology to the joint venture pertained to the Chinese market. The acquisition will

The approval will allow Pfizer to treat adults and children two years and older with relapsed or refractory CD33-positive AML with Mylotarg. Mylotarg is an antibody-drug conjugate that

Under the terms of a definitive purchase agreement executed by the companies, Saol Therapeutics will acquire the three hyperimmune products currently marketed by Aptevo:  WinRho SDF for autoimmune

The findings, made by researchers at the University of Pittsburgh Center for Vaccine Research and National Institutes of Health, also show that an experimental drug may hold promise

The company has submitted biologics license application (BLA) with to the FDA for its long-acting site-specifically PEGylated recombinant human factor VIII to treat Hemophilia A. BAY94-9027 has been

Alpha-synuclein (α-synuclein) is an aggregation-prone protein that contributes to the development of PD. This protein is the major constituent of Lewy bodies, which are pathological protein aggregates that

The AVERTS-1 trial was a 16-week, prospective, randomized, double-blind, placebo-controlled trial that enrolled a total of 165 patients with unilateral Ménière’s disease in the United States. The clinical

Claimed to be the first of its kind approval, the FDA has approved Kymriah to treat patients up to 25 years of age with B-cell precursor ALL, which

The ADC programs covered in the deal are IMGN779 and IMGN632 with an additional program also expected to be designated during the agreement term. While IMGN779 is a